Gujarat Themis Biosyn Investor Presentation for Q2 & H1 FY26
Gujarat Themis Biosyn's Q2 FY26 revenue rose by 22% to ₹42.3 Cr, EBITDA by 36.3% to ₹20.9 Cr, and PAT by 35.3% to ₹14.3 Cr. The company has completed its fermentation block expansion.
The expansion of production capacity and strong financial results suggest a positive outlook for the company. The move into API production could also open new markets.
The announcement highlights strong financial performance in Q2 FY26, including significant growth in revenue, EBITDA, and PAT. The completion of the fermentation block expansion and commencement of commercial production are also positive developments.
* Gujarat Themis Biosyn Limited presented its Investor Presentation for Q2 & H1 FY26. * In Q2 FY26, the company's top line grew 22% year-on-year to ₹42.3 crore, EBITDA grew 36.3% to ₹20.9 crore, and PAT grew 35.3% to ₹14.3 crore. * EPS for the quarter is ₹1.31, while TTM EPS is ₹4.43. * In October 2025, the company completed the expansion of its new fermentation block, more than doubling the total capacity to 990 KL. Commercial production of existing products Rifa-S and Rifa-O has begun in the new unit. * The API facility is active with validation batches in progress, targeting key export markets. * R&D spend during the half-year was approximately 4% of revenue. * H1 FY26: Total Income from Operations ₹78.22 crore, EBITDA ₹34.86 crore, and PAT ₹23.33 crore. * Management Comment: Dr. Sachin Patel, Director, mentioned strong performance in Q2, increased production and sales volumes, and the completion of the fermentation block expansion.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.